Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2014

01-02-2014 | Letter

Malignant hyperthermia in the intensive care setting

Authors: Frank Schuster, Susanne Moegele, Stephan Johannsen, Norbert Roewer

Published in: Critical Care | Issue 1/2014

Login to get access

Excerpt

Malignant hyperthermia (MH) is a life-threatening, inherited disorder of skeletal muscle calcium homeostasis. In susceptible individuals, exposure to trigger agents such as volatile anesthetics and depolarizing muscle relaxants, typically administered to induce or maintain general anesthesia, may lead to a hypermetabolic muscular syndrome [1]. Recently, an anesthetic conserving device (AnaConDa®; Sedana Medical AB, Geretsried, Germany) was introduced for sedation of intensive care patients using volatile anesthetics, associated with shorter wake-up and extubation time, reduced duration of mechanical ventilation and earlier hospital discharge [2]. …
Literature
1.
Schuster F, Müller-Reible CR: Malignant hyperthermia – diagnostics, treatment and anaesthetic management. Anasthesiol Intensivmed Notfallmed Schmerzther 2009, 44: 758-763. 10.1055/s-0029-1242125CrossRefPubMed
2.
Misra S, Koshy T: A review of the practice of sedation with inhalational anaesthetics in the intensive care unit with the AnaConDa ® device. Indian J Anaesth 2012, 56: 518-523. 10.4103/0019-5049.104565PubMedCentralCrossRefPubMed
3.
European Malignant Hyperpyrexia Group: A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984, 56: 1267-1269.CrossRef
Metadata
Title
Malignant hyperthermia in the intensive care setting
Authors
Frank Schuster
Susanne Moegele
Stephan Johannsen
Norbert Roewer
Publication date
01-02-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc13744

Other articles of this Issue 1/2014

Critical Care 1/2014 Go to the issue

Research

Statin therapy reduces oxidized low density lipoprotein level, a risk factor for stroke outcome

Commentary

Detrimental role of humoral signalling in cardio-renal cross-talk

Commentary

Missing link or not, mobilise against delirium

Review

Incretins and the intensivist: what are they and what does an intensivist need to know about them?

Letter

Back to basics in sepsis treatment: critically ill patients need intensive care

Research

Multiple gene-to-gene interactions in children with sepsis: a combination of five gene variants predicts outcome of life-threatening sepsis